New research in macrolides and ketolides since 1997

Bibliography

• BRYSKIER A, AGOURIDAS C, CHANTOT JF: Ketolides: new semi-synthetic 14-membered ring macrolides. In: Expanding Indications For The New Macrolides, Azalides And Streptogramins. Zinner SH, Young LS, Acar JF, Neu HC (Eds). Marcel Dekker (1998)39–50.
   Google Scholar
• BRYSKIER A: Novelties in the field of macrolides. Exp. Opin. Invest. Drugs (1997) 6:1697–1709.
   PubMedGoogle Scholar
• WEISBLUM B: Erythromycin resistance by ribosomal modification. Antimicrob. Agents Chemother. (1995) 39:577–585.
   PubMed Web of Science ®Google Scholar
• MAO JCH, PUTTERMANN M: The intermolecularcomplex of erythromycin and ribosomes. J. Mol (1969) 44:347–361.
   PubMed Web of Science ®Google Scholar
• CHANTOT J-F; BRYSKIER A, GASC J-C: Antibacterial activity of roxithromycin a laboratory evaluation. J. Antibiotics (1986) 39:660–668.
   PubMed Web of Science ®Google Scholar
• BRYSKIER A: Newer macrolides and their potential target organisms. Curr. Opin. Infect. Dis. (1992) 5:764–772.
   Web of Science ®Google Scholar
• BRYSKIER A: Roxithromycin: Antimicrobial activity. J.Antimicrob. Chemother. (1998) 41 (Suppl. B):1–21
   Google Scholar
• CHAMPNEY WS, BURDINE R: Macrolide antibioticsinhibit 50S ribosomal subunit assembly in Bacillus subtilis and Staphylococcus aureus. Antimicrob. Agents Chemother. (1995) 39:2141–2144.
   PubMed Web of Science ®Google Scholar
• CHAMPNEY WS, BURDINE R: Macrolide antibioticinhibition of translation and 50S ribosomal subunit assembly in methicillin-resistant Staphylococcus aureus cells. Microbic]. Drug Resist. (1998) 4:169–174.
   PubMed Web of Science ®Google Scholar
• CHAMPNEY WS, BURDINE R: 50S ribosomal subunit synthesis and translation are equivalent targets for erythromycin inhibition in Staphylococcus aureus. Antimicrob. Agents Chemother. (1996) 40:1301–1303.
   PubMed Web of Science ®Google Scholar
• CHAMPNEY WS, TOBER CL, BURDINE R: A comparisonof the inhibition of translation and 505 ribosomal subunit formation in Staphylococcus aureus cells by nine different macrolides antibiotics. Curr. Microbiol. (1998) 37:412–417.
   PubMed Web of Science ®Google Scholar
• ANDERSON M, BERGERON J, MASAMUNE H, NORCIA M,RETSEMA J, SUTCLIFFE J: Activity of CP 227, 182, a descladinose 3 keto clarithromycin derivative, in cell free peptide synthesis and ribosome binding studies. Frontiers in translation, Victoria, BC, Canada (1995) Abstract 288:145.
   Google Scholar
• GOLDMAN RC, KADAM SK: Binding of novel macrolidestructures to macrolide-lincosamide-streptogramin B-resistant ribosomes inhibits protein synthesis and bacterial growth. Antimicrob. Agents Chemother. (1989) 33:1058–1066.
   PubMedGoogle Scholar
• CHAMPNEY WS, TOBER CL: Inhibition of translationand 505 ribosomal subunit formation in Staphylo-coccus aureus cells by 11 different ketolide antibi-otics. Curr. Microbiol. (1998) 37:418–425.
   PubMed Web of Science ®Google Scholar
• MENNINGER JR, OTTO P: Erythromycin, carbomycinand spiramycin inhibit protein synthesis by stimulating the dissociation of peptidyl-tRNA from ribosomes. Antimicrob. Agents Chemother. (1988) 21:810–818.
   Web of Science ®Google Scholar
• XIONG L, SHAH S, MAUVAIS P, MANKIN AS: A ketolideresistance mutation in domain II of 23S rRNA reveals the proximity of hairpin 35 to the peptidyl transferase centre. Mol. Microb. (1999) 31:633–639.
   PubMed Web of Science ®Google Scholar
• HANSEN LH, MAUVAIS P, DOUTHWAITE S: The macrolide-ketolide antibiotic binding site is formed by structures in domain II and V of 23S ribosomal RNA. Mol. Microb. (1999) 31:623–631.
   PubMed Web of Science ®Google Scholar
• HOSOYAMA T, YUGE T, TAKAHASHI S et al.: Inhibitoryeffect of antimicrobial agents on alginate production in Pseudomonas aeruginosa. J. Antibiotics (1999) 52:65–67.
   PubMed Web of Science ®Google Scholar
• LABRO MT: Immunological effects of macrolides. Curr.Opin. Infect. Dis. (1998) 11:681–688.
   PubMed Web of Science ®Google Scholar
• SUNAZUKA T, TAKIZAWA H, DESAKI M et al: Effects oferythromycin and its derivatives on interleukin-8 release by human bronchial epithelial cell line BEAS-2B cells. J. Antibiotics (1999) 52:71–74.
   PubMed Web of Science ®Google Scholar
• BRYSKIER A, AGOURIDAS C, GASC J-C: Classification ofmacrolide antibiotics. In: Macrolides, Chemistry, Pharmacology and Clinical Uses. Bryskier AJ, Butzler J-P, Neu HC, Tulkens PM (Eds.) Arnette/Blackwell, Paris (1993).
   Google Scholar
• BRYSKIER A, AGOURIDAS C, CHANTOT JF: Ketolide:novel antibacterial agent designed to overcome erythromycin A resistance. Proceedings of ICMASK IV (In Press).
   Google Scholar
• FERNANDES PB, BAKER WR, FREIBERG LA, HARDY DJ,MC DONALD ED: New macrolides active against Streptococcus pyogenes with inducible or constitutive type of macrolide-lincosamide-streptogramin B resistance. Antimicrob. Agents Chemother. (1989) 33:78–85.
   PubMed Web of Science ®Google Scholar
• SU WG: Novel macrolide C-4" carbamate derivative:chemistry and structure activity relationship. 3rd International Antibacterial Drug Discover)/ and Develop-ment. Princeton, USA March 8–9 (1999).
   Google Scholar
• ANDERSON M, BERGERON J, BLAIR K et al: In vitro and in vivo activity and mechanism of action of CP 279,107 a C-4" bisaryl erythromycylamine derivative with potent activity against macrolide-resistant strepto-cocci. 38th Intel-se" Con! Antimicrob. Agents Chemother. San Diego (1998) Abstract F-128:264.
   Google Scholar
• BRENNAN L, DUIGNAN J, PETITPAS J et al.: CP 544 372: MICso studies and killing kinetics against key respira-tory tract pathogens. 38th Intel-se" Con! Antimicrob. Agents Chemother. San Diego (1998) Abstract F-124:264.
   Google Scholar
• WU SG, SMYTH KT, RAINVILLE JP et al: Novel erythro-mycylamine 4"-carbamate antibacterial agents: synthesis and biological evaluation resulting in discovery of CP-544, 372. 38th Intel-se" Con! Antimicrob. Agents Chemother. San Diego (1998) Abstract F-122:263.
   Google Scholar
• WU YJ, WONS R Jr, DURKIN D et al: Synthesis and in vitro activity as novel C-4 carbamates derivatives of 14-and 15-membered macrolides. 38th Intersci. Con! Antimicrob. Agents Chemother. San Diego, USA (1998) Abstract F-123:263.
   Google Scholar
• GIRARD D, MATHIEU HVV, GIRARD AE et al: In vivo oralefficicacy of CP-544, 372, a new erythromycylamine C4 carbamate, against macrolide-resistant pneumococci and Haemophilus influenzae. 38th Intersci. Con! Antimicrob. Agents Chemother. San Diego, USA (1998) Abstract F-121:263.
   Google Scholar
• GIRARD D, MATHIEU HW, GIRARD AE, SU WG, SMYTHKT, RAINVILLE JP: Pharmacokinetics and pharmacody-namics of CP-544, 372, a new erythromycylamine C4 carbamate, in murine pneumococcal pulmonary infections. 38th Intersci. Con! Antimicrob. Agents Chemother. San Diego, USA (1998) Abstract F-120:262.
   Google Scholar
• CHU DTW: Gene manipulation in the discovery of novel macrolides. 3rd International Antibacterial Drug Discovery and Development. Princeton, USA March 8–9 (1999).
   Google Scholar
• MIKAMI Y, YAZAWA K, NEMOTO A, KOMAKI H, TANAKAY, GRAFE U: Production of erythromycin E by pathogenic Nocardia Brasiliensis. J. Antibiotics (1999) 52:201–202.
   PubMed Web of Science ®Google Scholar
• PACEY MS, DIRLAM JP, GELDART RW et al.: Novelerythromycin from a recombinant Saccharopoly-spora erythrea strain NRRL 2338 pIG/1.I. Fermenta-tion, isolation and biological activity. J. Antibiotics (1998) 51:1029–1034.
   Google Scholar
• PARSON IC, EVERETT JR, PACEY MS, RUDDOCK JC, SWANSON AG, THOMPSON CM: Structural elucidation of a novel erythromycin, 13-cyclopenty1-13-desethyl erythromycin B, from a recombinant Saccharopoly-spora erythrea strains, NRRL 2338 pIG/1. J. Antibiotics (1999) 52:190–192.
   PubMedGoogle Scholar
• CLARK RF, OR YS, MA Z et al.: Novel 6-0-substitutederythromycin A derivatives: synthesis and antibacte-rial activity. 38th Intersci. Con! Antimicrob. Agents Chemother. San Diego, USA (1998) Abstract F-125:264.
   Google Scholar
• MORIMOTO S, WATANABE Y, OMURA S: Chemical modification of erythromycins. II-synthesis and bacterial activity of O-alkyl derivatives of erythro-mycin A. J. Antibiotic (1990) 3:286–294.
   Google Scholar
• BRYSKIER A, AGOURIDAS C: Azalides: a new medicinalchemical family. Curr. Opin. Invest. Drugs. (1993) 2:687–694.
   Google Scholar
• WADDELL ST, SANTORELLI GM, BLIZZARD TA, GRAHAMA, OCCI J: Synthesis and antibacterial activity of O-methyl derivatives of azalide antibiotics: 1-4", 11 and 12-0Me via direct methylation. Bioorg. Med. Chem. Lett. (1998) 8:549–554.
   PubMed Web of Science ®Google Scholar
• KOBREHEL G, LAZAREVSKI G, DOKIC S, KOLAONY-BABIC L, KUOISEC-TEPES N, CURLJE M: Synthesis and antibacterial activity of O-methyl azithromycin deriva-tives. J. Antibiotics (1992) 45/4:527–534.
   Google Scholar
• WADDELL ST, SANTORELLI GM, BLIZZARD TA, GRAHAMA, OCCI J: Synthesis and antibacterial activity of O-methyl derivatives of azalide antibiotics: 6-0me derivatives via clarithromycin. Bioorg. Med. Chem. Lett. (1998) 8:1321–1326.
   PubMed Web of Science ®Google Scholar
• KURIBRARA KI, AJITO K, SHIBAHARA S et al.: Cladinoseanalogue of sixteen-membered macrolide antibiotics. VI - Synthesis of metabolically programmed highly potent analogues of sixteen-membered macrolide antibiotics. J. Antibiotics (1998) 51:771–785.
   Google Scholar
• BERGOGNE-BEREZIN E, DRUGEON H, MIGNOT A, GUILLAUME M: The suppository form of antibiotic administration revisited: improvement of rectal bioavailability of macrolides. Update of spiramycin. 38th Intersci. Con! Antimicrob. Agents Chemother. San Diego (1998) Abstract A-101:32.
   Google Scholar
• PORAS H, KUNESH G, BARRIÈRE JC, BERTHAUD N, ANDREMONT A: Synthesis and in vitro antibacterial activity of catechol spiramycin conjugate. J. Antibiotics (1998) 51:786–796.
   PubMed Web of Science ®Google Scholar
• NARANDA A, LOPOTAR N: New derivatives of tylosin-IV-dihydro and tetrahydro desmycosin oximes. J. Antibiotics (1999) 52:68–70.
   PubMed Web of Science ®Google Scholar
• KELEMEN GH, ZALACAIN M, CULEBRAS E, SENO ET, CUNDLIFFE E: Transcriptonal a attenuation control of the tylosin resistance gene trla in Streptomyces fradiae. Mol. Microbiol. (1994) 14:833–842.
   PubMed Web of Science ®Google Scholar
• WILSON VTW, CUNDLIFFE E: Molecular analysis of trigan antibiotic - resistance gene from tylosin - producing Streptomyces fradiae, and discovery of a novel resistance mechanism. J. Antibiotics (1999) 52:288–296.
   PubMed Web of Science ®Google Scholar
• MCFARLAND JM, HECKER SJ, JAYNES BJ et al.:Repromicin derivatives with potent antibacterial activity against Pasteurella multocida. J. Med. Chem. (1997) 40:1041–1045.
   PubMed Web of Science ®Google Scholar
• NORCIA LJL, SEIBEL SB, KAMICKLER BJ et al.: In vitromicrobiological characterization of novel macrolide-CP-163, 505 for animal health specific use. J. Antibiotics (1998) 51:136–144.
   PubMed Web of Science ®Google Scholar
• NORCIA LJJ, SILVIA AM, HAYASHI SF: Studies on Time-Kill kinetics of different classes of antibiotics against veterinary pathogenic bacteria including Pasteurella, Actinobacillus and Escherichia coli. J. Antibiotics (1999) 52:52–60.
   PubMed Web of Science ®Google Scholar
• LE MAHIEU R, CARSON M, KIERSTEAD RW, FERN LM, GRUNBERG DF: Glycoside cleavage reactions on Erythromycin A. Preparation of erythronolide A. J. Med. Chem. (1974) 17:953–956.
   PubMed Web of Science ®Google Scholar
• AGOURIDAS C, DENTS A, AUGER JM et al.: Synthesis and antibacterial activity of ketolides (6-0-methyl-3-oxo erythromycin derivatives) a new class of antibacterial highly potent against macrolide-resistant and -susce-ptible respiratory pathogens. J. Med. Chem. (1998) 41:4080–4100.
   PubMed Web of Science ®Google Scholar
• BRYSKIER A: Novelties in the field of anti-infectives in1997. Clin. Infect. Dis. (1998) 27:865–883.
   PubMed Web of Science ®Google Scholar
• PHAN LT, OR YS, CHEN Y: 2-substituted tricyclic ketolides: New antibacterial macrolides. Synthesis and biological activity. 38th Intersci. Conf Antimicrob. Agents Chemother. San Diego, USA (1998) Abstract F-127:264.
   Google Scholar
• MA Z, OR YS, CLARK RF: Synthesis and antibacterial activity of 6-0-substituted ketolides. 38th Intersci. Conf Antimicrob. Agents Chemother. San Diego, USA (1998) Abstract F-126:264.
   Google Scholar
• NILIUS AM, BUT M, ALMER L et al.: Comparative in vitroactivity of AB-733, a novel antibacterial ketolides. Microbiol. Infect. (1999) 5 (Suppl. 3):177.
   Google Scholar
• SHORTRIDGE D, RAMER N, DARWISH A, FLAMM RK: Activity of the ketolide ABT-773, as measured by microbroth dilution against macrolide susceptible and macrolide resistant Streptococcus spp. Microbiol. Infect. (1999) 5 (Suppl. 3):78 Abstract 132.
   Google Scholar
• EWING PA, MITTEN MJ, MEULBROEK JA, SHORTRIDGE D, ALDER JD: Efficacy of ABT-773 against acute systemic bacterial infections in mice caused by resistant Streptococcus pneumoniae. Gun. Microbiol. Infect. (1999) 5\(Suppl. 3):179.
   Google Scholar
• DENTS A, AGOURIDAS C: Synthesis of 6-0-methyl azithromycin and its ketolide analogue via Beckmann rearrangement of (E)-6-0-methyl erythromycin oxime. Bioorg. Med. Chem. Lett. (1998) 8:2427–2432.
   PubMed Web of Science ®Google Scholar